Using Biologic Agents in Pediatric Rheumatologic Diseases

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)


Volume 15, 3 Issues, 2016


Download PDF Flyer




Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Claudiu T. Supuran
Neurofarba Department
University of Florence
Florence
Italy


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Using Biologic Agents in Pediatric Rheumatologic Diseases



Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 9(1): 41-45.

Author(s): Erbil Unsal.

Affiliation: Dokuz Eylul University, Faculty of Medicine, Dept. of Pediatrics, Ped. Rheumatology Unit, Balcova 35340 Izmir, Turkey.

Abstract

Juvenile Idiopathic Arthritis (JIA) is an “umbrella” term which is used to cover Juvenile Rheumatoid Arthritis (JRA) and Juvenile Chronic Arthritis (JCA). Biologic agents are needed when others like NSAIDs (Non-steroidal antiinflammatory agents), DMARDs (Disease modifying antirheumatic drugs) cannot provide or maintain clinical remission, and patients are mainly bound on steroids, which are potential anti-inflammatory drugs with serious well-known side effects to the growing child. TNF-α antagonists are the first anti-cytokine agents introduced in the last decade. However, there are important subtypes, such as systemic JIA which are resistant to these drugs, because IL-1 β (Interleukin 1 β) activation is shown to be the main pathway. One of the most frequently asked questions about biologics, particularly ETN (Etanercept), is the duration of the treatment, regarding both the safety and efficacy. Regarding the current literature, ETN seems to be effective and safe in treating the children with JIA. The high dose regimen (6 mg/kg) of infliximab, a TNF monoclonal antibody, has achieved better results on JIA and is now used in pediatric rheumatology practice. Adalimumab, another TNF inhibitor and abatacept (CTLA-4) were also shown to be effective and safe in JIA. Anakinra, canakinumab, and tocilizumab are the ones recently studied, and they are shown to be effective particularly for systemic arthritis.

Keywords:

Juvenile idiopathic arthritis, treatment, biologic agents.



Download Free Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 9
Issue Number: 1
First Page: 41
Last Page: 45
Page Count: 5
DOI: 10.2174/187152310790711629
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science